Why TG Therapeutics (TGTX) Stock Crashed 40% Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
November 30, 2021 12:55 PM ESTGoldman Sachs analyst Corinne Jenkins lowered the price target on TG Therapeutics (NASDAQ: TGTX) to $13.00 (from $26.00) while maintaining a Sell rating as the ODAC raises new questions on benefit/risk of U2 in CLL.
"Timing of approval decision likely delayed, approvability of U2 in CLL in question," the analyst notes.
... More
